Compare MYND & CASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYND | CASI |
|---|---|---|
| Founded | 1998 | 1991 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.4M | 19.7M |
| IPO Year | 2017 | 2023 |
| Metric | MYND | CASI |
|---|---|---|
| Price | $0.47 | $0.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 7.2K | ★ 15.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $0.74 |
| 52 Week High | $1.20 | $3.08 |
| Indicator | MYND | CASI |
|---|---|---|
| Relative Strength Index (RSI) | 47.47 | 20.63 |
| Support Level | $0.41 | N/A |
| Resistance Level | $0.58 | $1.07 |
| Average True Range (ATR) | 0.05 | 0.10 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 55.50 | 9.49 |
Mynd.ai Inc is a company that provides a platform for delivering digital content in K-12 classrooms, giving teachers seamless connectivity to inspire young minds. It features agnostic hardware that integrates across technology providers. Its product line includes a wide range of interactive tools and technologies, with its award-winning interactive displays at the forefront. It also offers interactive software apps such as Screen Share, computing modules, and accessories that meet the needs of customers, including K -12 educators, colleges and universities, small businesses and corporations, government agencies, and more. Geographically, it operates in United States and Rest of the world.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.